B/F/TAF Switch Study for HIV-HBV Coinfection
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hepatitis B
- HIV -1 Infection
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is an open-label phase 4 switch study to evaluate the efficacy, safety, and tolerability of FDC B/F/TAF in adults with HIV-1 and HBV coinfection.Masking: None (Open Label)Masking Description: This is an open label studyPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03797014
- Collaborators
- Gilead Sciences
- Investigators
- Principal Investigator: Joel V Chua, MD Institute of Human Virology, University of Maryland
Get Well Soon